Conditions: Bladder Cancer Urinary Bladder
Keywords: Bladder Urinary CISPLATIN GEMCITABINE SU011248 (Sunitinib Malate) 08-159
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 18
Healthy volunteers: no

Brief summary:
The purpose of this study is to find out if using the combination of standard chemotherapy (gemcitabine and cisplatin) plus this new targeted pill (sunitinib) can help shrink your tumor before you undergo surgery for your bladder cancer.

Detailed description:

Arms:
arm 1: This is a phase II study of GCS (Gemcitabine, Cisplatin, and Sunitinib) as neoadjuvant chemotherapy in patients with muscle-invasive urothelial carcinoma of the bladder. Patients with muscle invasive urothelial carcinoma who are candidates for radical cystectomy will be enrolled.

Interventions: intervention 1: Sunitinib intervention 2: Gemcitabine intervention 3: cisplatin
Intervention descriptions: intervention 1: Sunitinib will be administered at a dose of 25mg orally once daily for 2 consecutive weeks followed by a 1 week rest period. intervention 2: Gemcitabine 1,000 mg/m\^2 intervention 3: cisplatin 35 mg/m\^2 will be administered intravenously on days 1 and 8.

Protocol document: